Cosmogenic Nuclide Systematics and the CRONUScalc Program

As cosmogenic nuclide applications continue to expand, the need for a common basis for calculation becomes increasingly important. In order to accurately compare between results from different nuclides, a single method of calculation is necessary. Calculators exist in numerous forms with none matching the needs of the CRONUS-Earth project to provide a simple and consistent method to interpret data from most commonly used cosmogenic nuclides. A new program written for this purpose, CRONUScalc, is presented here. This unified code presents a method applicable to 10Be, 26Al, 36Cl, 3He, and 14C, with 21Ne in testing. The base code predicts the concentration of a sample at a particular depth for a particular time in the past, which can be used for many applications. The multi-purpose code already includes functions for performing production rate calibrations as well as calculating erosion rates and surface exposure ages for single samples and depth profiles. The code is available under the GNU General Public License agreement and can be downloaded and modified to deal with specific atypical scenarios

DYNAMO - I. A sample of H alpha-luminous galaxies with resolved kinematics

DYNAMO is a multiwavelength, spatially resolved survey of local (z ∼ 0.1) star-forming galaxies designed to study evolution through comparison with samples at z _ 2. Half of the sample has integrated Hα luminosities of >1042 erg s−1, the typical lower limit for resolved spectroscopy at z _ 2. The sample covers a range in stellar mass (109–1011M_) and star formation rate (0.2–100M_ yr−1). In this first paper of a series, we present integral-field spectroscopy of Hα emission for the sample of 67 galaxies. We infer gas fractions in our sample as high as _0.8, higher than typical for local galaxies. Gas fraction correlates with stellarmass in galaxies with star formation rates below 10M_ yr−1, as found by COLDGASS, but galaxies with higher star formation rates have higher than expected gas fractions. There is only a weak correlation, if any, between gas fraction and gas velocity dispersion. Galaxies in the sample visually classified as disc-like are offset from the local stellar mass Tully–Fisher relation to higher circular velocities, but this offset vanishes when both gas and stars are included in the baryonic Tully–Fisher relation. The mean gas velocity dispersion of the sample is_50 km s−1, and V/σ ranges from 2 to 10 for most of the discs, similar to ‘turbulent’ galaxies at high redshift. Half of our sample show disc-like rotation, while ∼20 per cent show no signs of rotation. The division between rotating and non-rotating is approximately equal for the sub-samples with either star formation rates >10M_ yr−1, or specific star formation rates typical of the star formation ‘main sequence’ at z _ 2. Across our whole sample, we find good correlation between the dominance of ‘turbulence’ in galaxy discs (as expressed by V/σ ) and gas fraction as has been predicted for marginally stable Toomre discs. Comparing our sample with many others at low- and high-redshift reveals a correlation between gas velocity dispersion and star formation rate. These findings suggest the DYNAMO discs are excellent candidates for local galaxies similar to turbulent z _ 2 disc galaxies

Effective communication in business

ix+515hlm.;23c

Preservation of swallowing function with de-intensified chemoradiation therapy for HPV-associated oropharyngeal squamous cell carcinoma

Purpose: This study aimed to compare the swallowing function in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma treated with de-intensified chemoradiation therapy (6 weeks, 60 Gy) versus those receiving standard-of-care chemoradiation therapy (7 weeks, 70 Gy). Methods and materials: A retrospective review was conducted of 78 patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma with modified barium swallow studies pretreatment and 6 to 8 weeks posttreatment. The swallowing function was objectively scored for penetration, aspiration, and pharyngeal residue. Forty patients received de-intensified chemoradiation therapy (60 Gy image guided radiation therapy with weekly cisplatin 30 mg/m2) and 38 patients received standard-of-care chemoradiation therapy (70 Gy image guided radiation therapy with chemotherapy of the medical oncologist's choosing). Univariate and multivariate analyses were performed to detect differences between the cohorts with regard to laryngeal penetration, aspiration, and pharyngeal residue. A multivariate logistic regression was used to determine the overall effect of treatment on the swallowing function. Patient-reported swallowing outcomes in de-intensified cohort were assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Module for Head and Neck Cancer and the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events questionnaires. Results: Patients treated with de-intensified chemoradiation therapy were associated with a suggestion of lower risk of developing overall swallowing dysfunction (odds ratio [OR], 0.62; P = .07), laryngeal penetration (OR, 0.63; P = .12), and pharyngeal residue (OR, 0.61; P = .08). The mean pre- and 2-year post-European Organisation for Research and Treatment of Cancer Quality of Life scores pertaining to swallowing (1-4 scale, higher worse) in the de-intensified cohort were 1.4 and 1.2 for liquids; 1.2 and 1.1 for purees; 1.5 and 1.7 for solids, 1.0 and 1.3 for choked when swallowing; and 9.0 and 10.8 for composite score, respectively. The mean pre- and 2-year post-Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events swallowing difficulty scores (1-5 scale, with higher scores being worse) were 1.5 and 1.8, respectively. Conclusions: Compared with 7 weeks of 70 Gy, 6 weeks of 60 Gy de-intensified chemoradiation therapy appears to better preserve the baseline swallowing function (per objective modified barium swallow assessment). Patients treated with de-intensified chemoradiation therapy reported minimal changes in swallowing function

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.

BACKGROUND: Psilocybin is being studied for use in treatment-resistant depression. METHODS: In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the total score on the Montgomery-Åsberg Depression Rating Scale (MADRS; range, 0 to 60, with higher scores indicating more severe depression). Secondary end points included response at week 3 (≥50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score ≤10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits). RESULTS: A total of 79 participants were in the 25-mg group, 75 in the 10-mg group, and 79 in the 1-mg group. The mean MADRS total score at baseline was 32 or 33 in each group. Least-squares mean changes from baseline to week 3 in the score were -12.0 for 25 mg, -7.9 for 10 mg, and -5.4 for 1 mg; the difference between the 25-mg group and 1-mg group was -6.6 (95% confidence interval [CI], -10.2 to -2.9; P<0.001) and between the 10-mg group and 1-mg group was -2.5 (95% CI, -6.2 to 1.2; P = 0.18). In the 25-mg group, the incidences of response and remission at 3 weeks, but not sustained response at 12 weeks, were generally supportive of the primary results. Adverse events occurred in 179 of 233 participants (77%) and included headache, nausea, and dizziness. Suicidal ideation or behavior or self-injury occurred in all dose groups. CONCLUSIONS: In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder. (Funded by COMPASS Pathfinder; EudraCT number, 2017-003288-36; ClinicalTrials.gov number, NCT03775200.)